Rituximab label reflects updated warnings.(SAFETY CONCERNS)(Brief article)Smart, Michael
Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Ri...
Define rituximab. rituximab synonyms, rituximab pronunciation, rituximab translation, English dictionary definition of rituximab. n. A chimeric monoclonal antibody used to treat certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and ref
Brand names:Riabni,Rituxan,Ruxience,Truxima Dosage form:intravenous solution (10 mg/mL; abbs 10 mg/mL; arrx 10 mg/mL; pvvr 10 mg/mL) Drug classes:Antirheumatics,CD20 monoclonal antibodies Medically reviewed byPhilip Thornton, DipPharm. Last updated on Mar 10, 2025. ...
本发明的发明人采用体外低浓度梯度递增法,成功构建rituximab耐药细胞株,并通过label-free技术对耐药机制进行了初步研究,发现了多个蛋白标志物。该细胞模型及研究结果为进一步研究rituximab耐药及克服耐药提供了依据。 附图说明 图1为sds-page电泳图。 图2为肽段离子得分分布图。
Rituxan®(利妥昔单抗[rituximab])使用说明书2013年9月24日修订 版 http://.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5414lbl.pdf 汤教授注:在与罗氏集团成员Genentech公司2013年的Rituxan®(利妥昔单 抗[rituximab])使用说明书详细比较后发现两份说明书提供的资料在许多细节 方面不同,书写格式...
Rituxan®(利妥昔单抗[rituximab])使用说明书2013年9月24日修订版 http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103705s5414lbl.pdf 汤教授注:在与罗氏集团成员Genentech公司2013年的Rituxan® (利妥昔单抗[rituximab])使用说明书详细比较后发现两份说明书提供的资料在许多细节方面不同,书写格式...
on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label. ...
The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 10...
Biogen Idec(NASDAQ:BIIB),Genentech(NYSE:DNA) andRoche(SWX:ROG) said rituximab plus chemotherapy met the primary endpoint of a significant increase in progression-free survival (PFS) vs. chemotherapy alone in the open-label, international Phase III REACH trial in 552 patients with relapsed or ref...